Author

F. F. Marsili

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

J. L. Silva· 3 shared R. G. F. Alvim· 3 shared T. M. Lima· 3 shared A. M. O. Gomes· 2 shared A. Tanuri· 2 shared C. H. Dumard· 2 shared L. R. Castilho· 2 shared T. M. L. Souza· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. L. Silva

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Uncovering the structural flexibility of SARS-CoV-2 glycoprotein spike variants

H. R. S. Arruda, T. M. Lima, R. G. F. Alvim, F. B. A. Victorio, D. P. B. Abreu, F. F. Marsili, K. D. Cruz, P. Sosa-Acosta, M. Quinones-Vega, J. S. Guedes, F. C. S. Nogueira, J. L. Silva, L. R. Castilho, G. A. P. de Oliveira

The paper compares structural flexibility and stability of SARS-CoV-2 spike variants, finding D614G has less hydrophobic surface exposure and trimer persistence, potentially supporting its fitness advantage.

bioRxiv · Apr 20, 2022 · PreprintBiochemistry

Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum

J. d. Santos, L. F. Cruz, A. M. d. Fonseca-Martins, D. O. Maciel, G. G. Perez, V. A. Roncaglia-Pereira, C. H. Dumard, F. H. Guedes da Silva, A. C. V. dos Santos, M. S. Leandro, J. R. M. Ferreira, K. G. Pinto, L. Conde, D. A. S. Rodrigues, M. V. M. Silva, , H. L. de Matos Guedes

This study evaluates a vaccine strategy using Alum and Poly(I:C) adjuvants with SARS-CoV-2 spike protein, showing enhanced antibody and T-cell responses and reduced lung inflammation.

bioRxiv · Oct 5, 2021 · PreprintImmunology

Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy

L. E. R. Cunha, A. A. Stolet, M. A. Strauch, V. A. R. Pereira, C. H. Dumard, A. M. O. Gomes, P. N. C. Souza, J. G. Fonseca, F. E. Pontes, L. G. R. Meirelles, J. W. M. Albuquerque, C. Q. Sacramento, N. Fintelman-Rodrigues, T. M. Lima, R. G. F. Alvim, , J. L. Silva

This study produces potent equine antibodies against SARS-CoV-2 spike protein with high neutralizing titers, supporting a clinical trial for passive immunization therapy.

bioRxiv · Aug 17, 2020 · PreprintImmunology